Abstract
Background: Developing more potent antibacterial agents is one of the most important tasks of scientists in the health field due to the problem of antibiotic resistance. Among the antibiotic targets, we mention MurA (UDP-N-Acetylglucosamine Enolpyruvyl Transferase), which is a key enzyme of peptidoglycan biosynthesis of the bacterial cell wall.
Objective: Our objective was to search for new inhibitors of the bacterial enzyme MurA by docking the analogues of its inhibitor T6361, a derivative of 5-sulfonoxy-anthranilic acid.
Methods: 990 analogues of T6361 were docked in the first binding site of E.coli MurA (open form) using the FlexX program, and the ADME-Toxicity profile of the best ones was evaluated by SwissADME and PreADMET web servers.
Results: Docking results revealed two T6361 analogues to provide better energy scores than T6361, and have similar interactions with the binding site of E.coli MurA namely,3-{[2-(piperidine-1-carbonyl) phenyl]sulfamoyl}benzoic acid and 3-{[2-(pyrrolidine-1 carbonyl)phenyl]sulfamoyl}benzoic acid. Moreover, the two molecules were found to possess good pharmacokinetics and low toxicity.
Conclusion: We propose two analogues of T6361 as new potential inhibitors of MurA enzyme. Their good ADME-Toxicity profile qualifies them to reach in vitro and in vivo assays as future lead molecules.
Graphical Abstract
[1]
Levy SB, Marshall B. Antibacterial resistance worldwide: Causes, challenges and responses. Nat Med 2004; 10(S12): S122-9.
[http://dx.doi.org/10.1038/nm1145] [PMID: 15577930]
[http://dx.doi.org/10.1038/nm1145] [PMID: 15577930]
[2]
Zaman SB, Hussain MA, Nye R, Mehta V, Mamun KT, Hossain N. A review on antibiotic resistance: Alarm bells are ringing. Cureus 2017; 9(6): e1403.
[http://dx.doi.org/10.7759/cureus.1403] [PMID: 28852600]
[http://dx.doi.org/10.7759/cureus.1403] [PMID: 28852600]
[3]
Bengtsson-Palme J, Kristiansson E, Larsson DGJ. Environmental factors influencing the development and spread of antibiotic resistance. FEMS Microbiol Rev 2018; 42(1): 68-80.
[http://dx.doi.org/10.1093/femsre/fux053] [PMID: 29069382]
[http://dx.doi.org/10.1093/femsre/fux053] [PMID: 29069382]
[4]
Morris GM, Lim-Wilby M. Molecular docking. Methods Mol Biol 2008; 443: 365-82.
[http://dx.doi.org/10.1007/978-1-59745-177-2_19] [PMID: 18446297]
[http://dx.doi.org/10.1007/978-1-59745-177-2_19] [PMID: 18446297]
[5]
Brooijmans N, Kuntz ID. Molecular recognition and docking algorithms. Annu Rev Biophys Biomol Struct 2003; 32(1): 335-73.
[http://dx.doi.org/10.1146/annurev.biophys.32.110601.142532] [PMID: 12574069]
[http://dx.doi.org/10.1146/annurev.biophys.32.110601.142532] [PMID: 12574069]
[6]
Chaudhary KK, Mishra N. A review on molecular docking: Novel tool for drug discovery. JSM Chem 2016; 4(3): 1029.
[http://dx.doi.org/10.47739/2334-1831/1029]
[http://dx.doi.org/10.47739/2334-1831/1029]
[7]
Meng XY, Zhang HX, Mezei M, Cui M. Molecular Docking: A Powerful Approach For Structure-Based Drug Discovery. Current Computer-Aided Drug Design. Curr Comput Aided Drug Des 2011; 7(2): 146-57.
[http://dx.doi.org/10.2174/157340911795677602]
[http://dx.doi.org/10.2174/157340911795677602]
[8]
Van Heijenoort J. Biosynthesis of the bacterial peptidoglycan unit. In: Ghuysen JM, Hackenbeck R, Eds. Bacterial cell wall. (1st ed.). Amsterdam: Elsevier 1994; pp. 39-54.
[http://dx.doi.org/10.1016/S0167-7306(08)60406-8]
[http://dx.doi.org/10.1016/S0167-7306(08)60406-8]
[9]
Heijenoort J. Recent advances in the formation of the bacterial peptidoglycan monomer unit (1985 to 2000). Nat Prod Rep 2001; 18(5): 503-19.
[http://dx.doi.org/10.1039/a804532a] [PMID: 11699883]
[http://dx.doi.org/10.1039/a804532a] [PMID: 11699883]
[10]
Brown ED, Vivas EI, Walsh CT, Kolter R. MurA (MurZ), the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, is essential in Escherichia coli. J Bacteriol 1995; 177(14): 4194-7.
[http://dx.doi.org/10.1128/jb.177.14.4194-4197.1995] [PMID: 7608103]
[http://dx.doi.org/10.1128/jb.177.14.4194-4197.1995] [PMID: 7608103]
[11]
Schönbrunn E, Sack S, Eschenburg S, Perrakis A, Krekel F, Amrhein N. Crystal structure of UDP-N-acetylglucosamine enolpyruvyltransferase, the target of the antibiotic fosfomycin. Structure 1996; 4(9): 1065-75.
[http://dx.doi.org/10.1016/S0969-2126(96)00113-X] [PMID: 8805592]
[http://dx.doi.org/10.1016/S0969-2126(96)00113-X] [PMID: 8805592]
[12]
Eschenburg S, Priestman MA, Abdul-Latif FA, Delachaume C, Fassy F, Schönbrunn E. A novel inhibitor that suspends the induced fit mechanism of UDP-N-acetylglucosamine enolpyruvyl transferase (MurA). J Biol Chem 2005; 280(14): 14070-5.
[http://dx.doi.org/10.1074/jbc.M414412200] [PMID: 15701635]
[http://dx.doi.org/10.1074/jbc.M414412200] [PMID: 15701635]
[13]
Moro WB, Yang Z, Kane TA, Brouillette CG, Brouillette WJ. Virtual screening to identify lead inhibitors for bacterial NAD synthetase (NADs). Bioorg Med Chem Lett 2009; 19(7): 2001-5.
[http://dx.doi.org/10.1016/j.bmcl.2009.02.034] [PMID: 19249205]
[http://dx.doi.org/10.1016/j.bmcl.2009.02.034] [PMID: 19249205]
[14]
Wu S, Bottini M, Rickert RC, Mustelin T, Tautz L. In silico screening for PTPN22 inhibitors: Active hits from an inactive phosphatase conformation. ChemMedChem 2009; 4(3): 440-4.
[http://dx.doi.org/10.1002/cmdc.200800375] [PMID: 19177473]
[http://dx.doi.org/10.1002/cmdc.200800375] [PMID: 19177473]
[15]
Kim J, Kim K, Kim DE, Chong Y. Identification of novel HCV RNA-dependent RNA polymerase inhibitors using pharmacophore-guided virtual screening. Chem Biol Drug Des 2008; 72(6): 585-91.
[http://dx.doi.org/10.1111/j.1747-0285.2008.00730.x] [PMID: 19090925]
[http://dx.doi.org/10.1111/j.1747-0285.2008.00730.x] [PMID: 19090925]
[16]
Cho Y, Ioerger TR, Sacchettini JC. Discovery of novel nitrobenzothiazole inhibitors for Mycobacterium tuberculosis ATP phosphoribosyl transferase (HisG) through virtual screening. J Med Chem 2008; 51(19): 5984-92.
[http://dx.doi.org/10.1021/jm800328v] [PMID: 18778048]
[http://dx.doi.org/10.1021/jm800328v] [PMID: 18778048]
[17]
Kiss R, Kiss B, Könczöl Á, Szalai F, Jelinek I, László V. Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening. J Med Chem 2008; 51(11): 3145-53.
[http://dx.doi.org/10.1021/jm7014777] [PMID: 18459760]
[http://dx.doi.org/10.1021/jm7014777] [PMID: 18459760]
[18]
Soukupová J, Bordoni C, Turnham DJ, Yang WW, Seaton G, Gruca A. The discovery of a novel antimetastatic Bcl3 inhibitor. Mol Cancer Ther 2021; 20(5): 775-86.
[http://dx.doi.org/10.1158/1535-7163.MCT-20-0283] [PMID: 33649105]
[http://dx.doi.org/10.1158/1535-7163.MCT-20-0283] [PMID: 33649105]
[19]
Babaoglu K, Page MA, Jones VC, McNeil MR, Dong C, Naismith JH. Novel inhibitors of an emerging target in Mycobacterium tuberculosis; substituted thiazolidinones as inhibitors of dTDP-rhamnose synthesis. Bioorg Med Chem Lett 2003; 13(19): 3227-30.
[http://dx.doi.org/10.1016/S0960-894X(03)00673-5] [PMID: 12951098]
[http://dx.doi.org/10.1016/S0960-894X(03)00673-5] [PMID: 12951098]
[20]
Molinspiration. Available from:
https://www.molinspiration.com/cgi-bin/properties (Accessed on March, 2022).
[21]
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46(1-3): 3-26.
[http://dx.doi.org/10.1016/S0169-409X(00)00129-0] [PMID: 11259830]
[http://dx.doi.org/10.1016/S0169-409X(00)00129-0] [PMID: 11259830]
[22]
Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002; 45(12): 2615-23.
[http://dx.doi.org/10.1021/jm020017n] [PMID: 12036371]
[http://dx.doi.org/10.1021/jm020017n] [PMID: 12036371]
[25]
Han H. The application of x-ray crystallography towards the design of novel inhibitors of MurA and CDK2. PhD thesis Lawrence: University of Kansas 2008.
[26]
Klein CD, Bachelier A. Molecular modeling and bioinformatical analysis of the antibacterial target enzyme MurA from a drug design perspective. J Comput Aided Mol Des 2006; 20(10-11): 621-8.
[http://dx.doi.org/10.1007/s10822-006-9062-2] [PMID: 17124631]
[http://dx.doi.org/10.1007/s10822-006-9062-2] [PMID: 17124631]
[28]
Han Y, Zhang J, Hu CQ, Zhang X, Ma B, Zhang P. In silico ADME and toxicity prediction of ceftazidime and its impurities. Front Pharmacol 2019; 10: 434.
[http://dx.doi.org/10.3389/fphar.2019.00434] [PMID: 31068821]
[http://dx.doi.org/10.3389/fphar.2019.00434] [PMID: 31068821]
[29]
Tristani-Firouzi M, Chen J, Mitcheson JS, Sanguinetti MC. Molecular biology of K+ channels and their role in cardiac arrhythmias11Am J Med. 2001;110-50-59. Am J Med 2001; 110(1): 50-9.
[http://dx.doi.org/10.1016/S0002-9343(00)00623-9] [PMID: 11152866]
[http://dx.doi.org/10.1016/S0002-9343(00)00623-9] [PMID: 11152866]
[30]
Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006; 440(7083): 463-9.
[http://dx.doi.org/10.1038/nature04710] [PMID: 16554806]
[http://dx.doi.org/10.1038/nature04710] [PMID: 16554806]
